Labcorp stock rallies as upward price move follows strong quarterly results and acquisition spree

Traders Union
All News
Stocks
Labcorp jumps 9.9% on Q3 results

Highlights

Labcorp reported third-quarter 2026 revenue of $3.81 billion, an increase of 6.9% to 7% year-over-year, and raised full-year guidance for adjusted earnings per share and sales.
The company announced four acquisitions, including assets from MLM Medical Labs and BioReference Health, and declared a $0.72 quarterly dividend with $255.5 million invested in acquisitions.
Labcorp stock surged 9.9% to $363.95, with technical signals overbought and the expected trading range for the next 2 to 3 days at $357.31 to $402.74.

Investor demand rises as results, acquisitions, and guidance boost sentiment

Labcorp reported third-quarter 2026 revenue of $3.81 billion, representing a 6.9%-7% increase year-over-year, which signals continued strength in its core diagnostics and services business and drives increased investor demand, according to PR Newswire. Following these robust results, the company raised its full-year guidance for both adjusted earnings per share and sales, indicating management’s confidence in persistent revenue and margin momentum. The announcement of four acquisitions—including assets from MLM Medical Labs and BioReference Health—expands Labcorp’s footprint and diversifies future growth drivers. A $0.72 quarterly dividend declared and $255.5 million invested in acquisitions further highlight the company’s proactive capital allocation and income appeal.

Bullish bias intensifies as major averages and indicators align

On the H1 chart, LH is positioned above the MA-20, MA-50, and the long-term MA-200, reinforcing the prevailing uptrend. The Ichimoku Kijun level at $344.41 serves as immediate support. Momentum indicators remain favorable, with MACD and ADX both registering buy signals. RSI, Stochastic RSI, CCI, and Bull/Bear Power are all in overbought territory, while the Awesome Oscillator confirms the strong bullish momentum.

Consolidation expected with high upside odds and limited downside

Over the next 2–3 trading days, LH is likely to trade in a broad range between $357.31 and $402.74, forming a volatility band relative to current levels. The probability of an upward move is very high (over 80%), while downside risk is minimal. The baseline scenario anticipates price action to consolidate within this range; a breakout above resistance could trigger a further rally, while a breach of immediate support may prompt a short-term pullback.

Anton Kharitonov, expert at Traders Union, sees Labcorp’s latest revenue growth and raised guidance as supportive, but remains cautious given the overbought readings across key momentum indicators. He notes that while acquisitions and the fresh dividend highlight active management, price risks remain elevated at these levels. Kharitonov believes consolidation is most likely in the near term, with any break of immediate support potentially triggering a pullback. "The trend looks stretched—until $344.41 is broken, I’m staying neutral and waiting for clearer direction."

Previously it was reported that Labcorp exhibited strong earnings-driven momentum, with analysts highlighting the potential for continued upside supported by technical strength. The current trading environment builds on this outlook, as expanding acquisitions and rising revenue reinforce an active uptrend, with the $344.41 Ichimoku Kijun serving as a critical support level for traders to monitor in the near term.

Source of Data: LH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.